ArticleDermatology and therapy2026

Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor.

Brittney Wass et al.PubMed ↗Publisher ↗

No numbers read from the abstract.